Page last updated: 2024-09-03

cgp 46381 and ethosuximide

cgp 46381 has been researched along with ethosuximide in 2 studies

Compound Research Comparison

Studies (cgp 46381)	Trials (cgp 46381)	Recent Studies (post-2010) (cgp 46381)	Studies (ethosuximide)	Trials (ethosuximide)	Recent Studies (post-2010) (ethosuximide)
25	0	5	1,096	37	206

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fukuda, H; Ishige, K; Ito, Y	1
Endo, H; Ishige, K; Ito, Y; Saito, H	1

Other Studies

2 other study(ies) available for cgp 46381 and ethosuximide

Article	Year
Pharmacological profiles of absence seizure-induced increases in CRE- and AP-1 DNA-binding activities in gamma-butyrolactone-treated mice. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1998, Volume: 18, Issue:4 Topics: 4-Butyrolactone; Activating Transcription Factor 2; Animals; Anticonvulsants; Brain; Brain Chemistry; Cerebral Cortex; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; DNA-Binding Proteins; Epilepsy, Absence; Ethosuximide; GABA Antagonists; Mice; Organophosphorus Compounds; Phosphinic Acids; Thalamus; Transcription Factor AP-1; Transcription Factors	1998
Repeated administration of CGP 46381, a gamma-aminobutyric acidB antagonist, and ethosuximide suppresses seizure-associated cyclic adenosine 3'5' monophosphate response element- and activator protein-1 DNA-binding activities in lethargic (lh/lh) mice. Neuroscience letters, 2001, Jan-19, Volume: 297, Issue:3 Topics: Animals; Anticonvulsants; Cerebellum; Cerebral Cortex; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Epilepsy, Absence; Ethosuximide; GABA Antagonists; GABA-B Receptor Antagonists; Hippocampus; Mice; Phosphinic Acids; Sleep Stages; Thalamus; Transcription Factor AP-1; Treatment Outcome	2001

Article

Year

Pharmacological profiles of absence seizure-induced increases in CRE- and AP-1 DNA-binding activities in gamma-butyrolactone-treated mice.

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1998, Volume: 18, Issue:4

Topics: 4-Butyrolactone; Activating Transcription Factor 2; Animals; Anticonvulsants; Brain; Brain Chemistry; Cerebral Cortex; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; DNA-Binding Proteins; Epilepsy, Absence; Ethosuximide; GABA Antagonists; Mice; Organophosphorus Compounds; Phosphinic Acids; Thalamus; Transcription Factor AP-1; Transcription Factors

1998

Repeated administration of CGP 46381, a gamma-aminobutyric acidB antagonist, and ethosuximide suppresses seizure-associated cyclic adenosine 3'5' monophosphate response element- and activator protein-1 DNA-binding activities in lethargic (lh/lh) mice.

Neuroscience letters, 2001, Jan-19, Volume: 297, Issue:3

Topics: Animals; Anticonvulsants; Cerebellum; Cerebral Cortex; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Epilepsy, Absence; Ethosuximide; GABA Antagonists; GABA-B Receptor Antagonists; Hippocampus; Mice; Phosphinic Acids; Sleep Stages; Thalamus; Transcription Factor AP-1; Treatment Outcome

2001